Digital JP Morgan Week 2025 – Trân Lê and Sohit Gatiganti pharmaphorum sits down for a quick chat with the Grove.AI team about their new AI agent for clinical trial recruitment.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.